One aspect of the present invention provides a tablet for the treatment of diseases that cause excess metal, such as iron, in a human or animal body, or diseases caused by excess metal in a human comprising Exjade® (deferasirox ) of formula I: or an acceptable pharmaceutical salt thereof present in an amount between 45% and 60% by weight based on the total weight of the tablet, said tablet has a reduced release under gastric conditions and rapid release at almost pH neutral or neutral pH. Typically,A drug that dissolves faster is much more exposed in human trials. Surprisingly, in this case, compared with commercial dispersible tablets, exjade TM (defirasirox) tablets, characterized by slow release, have much higher bioavailability and no impact on food, while the latter has faster dissolution rate, but its dissolution level is quite high. Reduce exposure Characteristics of compressible and swallowable sachets (oral ingestion),Because its decay and dissolution time only need to reach the expected contact level. 15 another aspect of the invention provides a cladding compression comprising (a) defirasirox or a pharmaceutically acceptable salt, and (b) at least one pharmaceutically acceptable precursor chemical.Un aspecto de la presente invención proporciona una tableta para el tratamiento de enfermedades que causan un exceso de metal, tal como hierro, en un cuerpo humano o animal, o enfermedades causadas por un exceso de metal en un humano que comprende Exjade® TM (deferasirox) de la fórmula I : o una sal farmacéutica aceptable del mismo presente en una cantidad entre 45% y 60% por peso con base en el peso total del comprimido, dicho comprimido tiene una liberación 5 reducida bajo condiciones gástricas y liberación rápida a pH casi neutro o a pH neutro. Típicamente, un fármaco que muestre disolución más rápida tendrá un nivel de exposición mucho mayor cuando se prueba humanos. Sorprendentemente, en el caso actual, las tabletas de Exjade TM (deferasirox) formuladas por
